Prostate Cancer | Specialty

Dr. Siddiqui on Likely Candidates to Develop Prostate Cancer

March 2nd 2015

Mohummad Minhaj Siddiqui, MD, assistant professor of surgery, University of Maryland School of Medicine, director of urologic robotic surgery, University of Maryland Marlene and Stewart Greenebaum Cancer Center, discusses a study which demonstrated men with testicular cancer are more likely to develop prostate cancer.

Dr. Ryan on the Long Term Safety of Abiraterone Use

February 27th 2015

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the final analysis of COU-AA-302.

Dr. Emmanuel Antonarakis on AR-V7 and Response to Taxanes in mCRPC

February 27th 2015

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses a study looking at androgen receptor splice variant 7 (AR-V7) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Crawford Discusses Improving Risk Stratification in Prostate Cancer With the CCP Assay

February 27th 2015

E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado, discusses the performance of the cell cycle progression (CCP) assay for prostate cancer.

Dr. Loblaw on Monitoring Men With Intermediate-Risk Prostate Cancer

February 27th 2015

Andrew Loblaw, MD, FRCPC, MSc, clinician scientist, radiation oncologist, Sunnybrook Health Sciences Centre, discusses a study that looked at using active surveillance to monitor men with intermediate-risk prostate cancer.

Abiraterone OS Benefit Prolonged After Crossover Adjustment in mCRPC

February 27th 2015

The beneficial effect of abiraterone acetate on overall survival in men with progressive metastatic CRPC in the COU-AA-302 study becomes even more pronounced after adjustment for crossover from placebo to active treatment.

No Survival Benefit From Adding Docetaxel to ADT in Hormone-Sensitive Prostate Cancer

February 27th 2015

Androgen deprivation therapy with or without chemotherapy led to similar survival in men with advanced, metastatic hormone-sensitive prostate cancer, an updated analysis of a randomized trial showed.

Immunointensification May Favorably Alter Survival in mCRPC

February 27th 2015

A phase I study conducted at the NIH, combining a fixed dose of PROSTVAC with escalating doses of the checkpoint inhibitor ipilimumab, produced encouraging survival results in mCRPC.

Analysis Shows Increase in Higher-Risk Prostate Cancers

February 23rd 2015

The proportion of men diagnosed with intermediate- or high-risk cancer, based on blood PSA level, increased by nearly 6% from 2011 to 2013.

Use With Caution: Active Surveillance in Patients With Intermediate-Risk Prostate Cancer

February 23rd 2015

The risk of dying from prostate cancer increased fourfold when active surveillance was used to monitor men with intermediate-risk disease compared with low-risk prostate cancer patients.

Men with Testicular Cancer More Likely to Develop Prostate Cancer

February 23rd 2015

A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared to those without a history of testicular cancer.

AR-V7 Not Predictive of Chemo Outcomes in mCRPC, But May Still Have Prognostic Value

February 23rd 2015

The spliced androgen receptor variant AR-V7 was not shown to be a biomarker for chemotherapy efficacy in advanced prostate cancer, according to a small prospective study presented in a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

Dr. Walsh Compares Open and Robotic-Assisted Radical Prostatectomy Operations

February 18th 2015

Patrick C. Walsh, MD, university distinguished service professor of urology, Johns Hopkins School of Medicine, discusses radical prostatectomy operations in the traditional open and robotic-assisted form.

ASCO Supports ACS Guidelines for Prostate Cancer Survivor Care

February 15th 2015

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer specialists and primary care physicians deliver high quality of care to patients with localized disease.

Radium-223 for Treatment of Prostate Cancer

February 13th 2015

Antiandrogen Resistance With AR-V7 in CRPC

February 13th 2015

Enzalutamide Offers Second Option in Pre-Chemo CRPC

February 13th 2015

Pre-Chemotherapy Abiraterone Acetate in CRPC

February 13th 2015

Integrating CHAARTED Findings Into Prostate Cancer Care

February 13th 2015

CHAARTED Trial Changes Practice in Prostate Cancer

February 13th 2015